Half-Year 2022 Financial and Clinical Trials Update

VABYSMO Roche Ophthalmology franchise: Vabysmo in nAMD At 112 weeks Q16W dosing increases to ≥ 60% Ph III (LUCERNE, TENAYA) in nAMD: Dosing intervals of patients at year 1 and 2 48 weeks TENAYA LUCERNE Q8W Q8W 20.3% 22.2% Q16W Q16W 44.9% 45.7% Q12W 34.0% Q12W 32.9% Q12W + Q16W 79.7% Q12W + Q16W 77.8% 112 weeks TENAYA LUCERNE ASRS NYC ANNUAL MEETING 2022 Q8W Q8W 18.8% 25.8% Q16W Q12W Q16W 59.0% 14.3% 66.9% Q12W 15.1% Q12W + Q16W 74.1% Q12W + Q16W 81.2% • New dual MoA to promote vascular stability, potentially leading to a more durable therapy with maintanance of long-term vision gains Proportion of patients achieving Q16W dosing increased from >45% at week 52 to ≥ 60% at week 112; Vabysmo given at interval of up to every 4 months achieved comparable vision gains and reductions in central subfield thickness (CST) versus aflibercept given every two months At two years of treatment Vabysmo was well tolerated. No cases of retinal vasculitis or occlusive retinal vasculitis were reported in the Ph III studies Ph Ill extension studies (AVONELLE-X in nAMD & Rhone-X in DME) for Vabysmo to generate long-term (up to 4 years) safety and tolerability data ongoing Demetriades A.-M. et al., ASRS conference 2022; nAMD-neovascular age-related macular degeneration; BCVA-best-corrected visual acuity; CST-central subfield thickness; DME-diabetic macular edema; Q16W-every 16 weeks; MoA-mechanism of action; Eylea (aflibercept) is a registered trademark/product of Regeneron 32 32

View entire presentation